Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/54081
Type
ArticleCopyright
Restricted access
Collections
- INI - Artigos de Periódicos [3504]
Metadata
Show full item record
NEW HIV PREVENTION APPROACHES: PROMISE, PRAXIS, AND PITFALLS
Affilliation
Harvard University. Harvard Medical School. Boston. MA, USA / The Fenway Institute. Fenway Health. Boston, MA, USA
Institute of HIV Research and Innovation. Bangkok, Thailand.
University of Zimbabwe. Clinical Trials Research Centre. Harare, Zimbabwe.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Institute of HIV Research and Innovation. Bangkok, Thailand.
University of Zimbabwe. Clinical Trials Research Centre. Harare, Zimbabwe.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Abstract
More than a decade since the demonstration that
antiretrovirals used for pre-exposure prophylaxis (PrEP)
were safe and effective in decreasing HIV transmission,
these medications remain underused, but continue to
be needed, given the persistent burden of incident HIV
infection, particularly in multiple sub-Saharan African
countries. In 2020, there were about 1,5 million new HIV
infections globally, representing a decline of only 31%
since 2010.
Oral tenofovir-based PrEP is highly effective,
but disparities remain due to lower PrEP uptake and
adherence among populations disproportionately
impacted by HIV. Less than a third of approximately
3 million people who could benefit from PrEP have used
it, with most PrEP users located in affluent countries.
Share